Compare Regeneron Pharmaceuticals Inc (REGN) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs United States Natural Gas Fund — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while United States Natural Gas Fund trades at $10.77 (market cap $522.93M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 146.1× United States Natural Gas Fund's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and United States Natural Gas Fund for 22 Days on average.
| REGN | UNG | |
|---|---|---|
Market Cap | $76.40B | $522.93M |
Volume | 626,381 | 33,973,188 |
Sector | Health | Commodities - Energy |
52-Week High | $852.03 | $16.90 |
52-Week Low | $557.73 | $9.63 |
Typical Hold Time | 107 Days | 22 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported a net income of $65.15 million in 2024, though revenue was $0.00, and maintains a strong balance sheet with total assets of $790.02 million and minimal liabilities. Recent news highlights volatility in natural gas markets due to geopolitical tensions and record U.S. production.
The outlook for UNG is mixed, with bullish technicals and solid profitability offset by revenue uncertainty and market risks. Key opportunities include potential price support from geopolitical events, while risks involve natural gas price fluctuations and high production levels pressuring margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
